Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: An observational study

Critical Care

Volumn 9, Issue 1, 2004, Pages

  Morgenthaler, Nils G ^a   Struck, Joachim ^a   Christ Crain, Mirjam ^b   Bergmann, Andreas ^a   Müller, Beat ^b  

^a BRAHMS AG   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Biomarkers; Diagnosis; Sepsis; Therapy monitoring

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; PROCALCITONIN;

ADULT; AGED; APACHE; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INTENSIVE CARE UNIT; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SURVIVAL; SURVIVOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BLOOD; CLASSIFICATION; INTENSIVE CARE UNIT; MIDDLE AGED; PREDICTION AND FORECASTING;

ADULT; AGED; AGED, 80 AND OVER; APACHE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEPSIS; SHOCK, SEPTIC;

EID: 33644877937     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc3015     Document Type: Article

References (48)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310
2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554
3. Cohen J: The immunopathogenesis of sepsis. Nature 2002, 420:885-891
4. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150
5. Riedemann NC, Guo RF, Ward PA: The enigma of sepsis. J Clin Invest 2003, 112:460-467
6. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C: Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002, 166:1197-1205
7. Riedemann NC, Guo RF, Ward PA: Novel strategies for thetreatment of sepsis. Nat Med 2003, 9:517-524
8. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997, 350:1349-1353
9. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ: Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998, 351:9-13
10. Ruskoaho H: Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003, 24:341-356
11. Vesely DL: Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life 2002, 53:153-159
12. Mazul-Sunko B, Zarkovic N, Vrkic N, Klinger R, Peric M, Bekavac-Beslin M, Novkoski M, Krizmanic A, Gvozdenovic A, Topic E: Proatrial natriuretic peptide hormone from right atria is correlated with cardiac depression in septic patients. J Endocrinol Invest 2001, 24:RC22-RC24
13. Hartemink KJ, Groeneveld AB, de Groot MC, Strack van Schijndel RJ, van Kamp G, Thijs LG: alpha-atrial natriuretic peptide, cyclic guanosine monophosphate, and endothelin in plasma as markers of myocardial depression in human septic shock. Crit Care Med 2001, 29:80-87
14. Berendes E, Van Aken H, Raufhake C, Schmidt C, Assmann G, Walter M: Differential secretion of atrial and brain natriuretic peptide in critically ill patients. Anesth Analg 2001, 93:676-682
15. Witthaut R, Busch C, Fraunberger P, Walli A, Seidel D, Pilz G, Stuttmann R, Speichermann N, Verner L, Werdan K: Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003, 29:1696-1702
16. Witthaut R: Science review: natriuretic peptides in critical illness. Crit Care 2004, 8:342-349
17. Buckley MG, Marcus NJ, Yacoub MH: Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci (Lond) 1999, 97:689-695
18. Cappellin E, Gatti R, Spinella P, De Palo CB, Woloszczuk W, Maragno I, De Palo EF: Plasma atrial natriuretic peptide (ANP) fragments proANP (1-30) and proANP (31-67) measurements in chronic heart failure: a useful index for heart transplantation? Clin Chim Acta 2001, 310:49-52
19. Daggubati S, Parks JR, Overton RM, Cintron G, Schocken DD, Vesely DL: Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res 1997, 36:246-255
20. Morgenthaler NG, Struck J, Thomas B, Bergmann A: Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004, 50:234-236
21. Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, Ritz R: Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000, 28:977-983
22. Muller B, Becker KL, Kranzlin M, Schachinger H, Huber PR, Nylen ES, Snider RH, White JC, Schmidt-Gayk H, Zimmerli W, et al.: Disordered calcium homeostasis of sepsis: association with calcitonin precursors. Eur J Clin Invest 2000, 30:823-831
23. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, Mantovani A: Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001, 29:1404-1407
24. Muller B, Peri G, Doni A, Perruchoud AP, Landmann R, Pasqualini F, Mantovani A: High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002, 72:643-649
25. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655
26. Anonymous: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874
27. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003, 29:530-538
28. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al.: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32:858-873
29. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363:600-607
30. Simon L, Gauvin F, Anre K, Saint-Louis P, Lacroix J: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004, 39:206-217
31. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr: Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004, 89:1512-1525
32. Lubbesmeyer HJ, Woodson L, Traber LD, Flynn JT, Herndon DN, Traber DL: Immunoreactive atrial natriuretic factor is increased in ovine model of endotoxemia. Am J Physiol 1988, 254:R567-R571
33. Aiura K, Ueda M, Endo M, Kitajima M: Circulating concentrations and physiologic role of atrial natriuretic peptide during endotoxic shock in the rat. Crit Care Med 1995, 23:1898-1906
34. Mitaka C, Nagura T, Sakanishi N, Tsunoda Y, Toyooka H: Plasma alpha-atrial natriuretic peptide concentrations in acute respiratory failure associated with sepsis: preliminary study. Crit Care Med 1990, 18:1201-1203
35. Mitaka C, Hirata Y, Makita K, Nagura T, Tsunoda Y, Amaha K: Endothelin-1 and atrial natriuretic peptide in septic shock. Am Heart J 1993, 126:466-468
36. Chua G, Kang-Hoe L: Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit Care 2004, 8:R248-R250
37. Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, McCabe C, Welch SB, Whitney A, O'Gara P, et al.: Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 2004, 363:203-209
38. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G, Schocken DD: Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 1994, 90:1129-1140
39. Hinson JP, Kapas S, Smith DM: Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000, 21:138-167
40. McLean AS, Huang SJ, Nalos M, Tang B, Stewart DE: The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. Crit Care Med 2003, 31:2611-2618
41. Giannitsis E, Katus HA: Still unresolved issues with brain-type natriuretic peptide measurement in the critically ill patient. Crit Care Med 2003, 31:2703-2704
42. Vincent JL, Sun Q, Dubois MJ: Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002, 34:1084-1093
43. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709
44. Ely EW, Bernard GR, Vincent JL: Activated protein C for severe sepsis. N Engl J Med 2002, 347:1035-1036
45. Vincent JL, Abraham E, Annane D, Bernard G, Rivers E, Van den Berghe G: Reducing mortality in sepsis: new directions. Crit Care 2002:S1-S8
46. Warren HS, Suffredini AF, Eichacker PQ, Munford RS: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002, 347:1027-1030
47. Siegel JP: Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med 2002, 347:1030-1034
48. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE: APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 1981, 9:591-597